Late stage trials in Brazil have shown promising results for China’s Synovac Biotech COVID-19 vaccine, this situation for public use, The Wall Street Journal Reported on Monday.
According to the newspaper, the first country to complete the third trial phase for Synovac vaccine has reached the phase three trial, the vaccine, Coronavac in Brazil. The experimental vaccine is also being tested in Indonesia and Turkey.
Sources involved in the development of the vaccine told the journal that test results in Brazil indicated that the Synovac vaccine was above the 50 percent threshold considered necessary by the scientific community for adequate protection against the virus.
São Paulo Governor João Doria said that the Brazilian federal government plans to vacate all of Sao Paulo in late July, a year faster than what the federal government has promised. Sao Paulo has about a fifth of the country’s population.
In October, Synovac reported that 10,000 Beijing residents had already been injected with its vaccine.
The news of the promising result from Synovac follows similar reports from the Chinese state-owned pharmaceutical company Cyanopharma about another potential vaccine.
The United Arab Emirates reported earlier this month that a vaccine candidate trial of Sinopharma indicated that it was 86 percent effective in preventing coronavirus and 100 percent effective in preventing moderate and severe cases of COVID-19. The United Arab Emirates approved Sinopharma vaccine on 10 December, becoming the first government to do so.